Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1 (no aplicable en España), 2 (Marcas y Diseños) y 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentran cerrados desde el 20/08/2025. La solicitud del Bono 4 sigue abierta. Más adelante se informará sobre la reapertura de estos Bonos
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
165
resultados
Última actualización
28/09/2025 [07:28:00]
Resultados 150 a 165 de 165
Resumen de: CN120392918A
The invention relates to the technical field of traditional Chinese medicine preparations, and particularly discloses preparation and application of a sixteen-component medicine-food homologous prescription for treating Alzheimer's disease and depression through intelligence development and depression, and the preparation method comprises the following steps: S1, weighing the medicinal materials according to the prescription dosage, cleaning, selecting, drying and crushing to 50-100 meshes; s2, adding water into the medicinal materials, decocting for 1-3 times, decocting for 0.5-2 hours each time, combining filtrates at 60 DEG C, and concentrating until the relative density is 1.10-1.30, wherein the amount of added water is 5-15 times of the weight of the medicinal materials; s3, treating the concentrated solution by an alcohol precipitation method, standing, and recovering ethanol to obtain an extract; s4, mixing the extract with auxiliary materials to prepare one of granules, capsules or tablets; according to the traditional Chinese medicine composition disclosed by the invention, through a multi-target synergistic effect, cognitive dysfunction and mood disorder of patients with senile dementia and depression are remarkably improved. The tonifying medicinal materials such as the astragalus membranaceus and the rhizoma polygonati in the formula can enhance cerebral blood flow, inhibit beta amyloid protein deposition and tau protein phosphorylation and delay neurodegenerative
Resumen de: TW202434616A
Compounds, compositions, uses, and methods for increasing cell viability of a dopaminergic neuron, or for preventing or treating dopaminergic neuronal death, are provided herein. In certain examples, methods for reducing symptoms and/or for preventing or treating Parkinson's disease in a subject in need thereof are provided which may include a step of treatment with a GDP-bound form of Rab1a (Rab1a<SP>GDP</SP>), one or more expressible nucleic acids encoding Rab1a<SP>GDP</SP>, or a combination thereof.
Resumen de: MX2025007590A
Provided herein a method of treating Juvenile Huntington disease in a subject in need thereof comprising orally administering a pharmaceutical composition comprising pridopidine and/or its analog or a pharmaceutically acceptable salt thereof.
Resumen de: CN120392737A
The invention relates to the technical field of biological medicines, and particularly discloses application of oridonin in preparation of a medicine for treating Alzheimer's disease. The oridonin provided by the invention can also improve the learning and memory ability of AD mice, and plays a certain role in relieving the progress of the Alzheimer's disease. Structural formula of oridonin: # imgabs0 #
Resumen de: CN120400247A
The invention provides a multi-target and multi-gene stable silencing vector and application thereof in nervous system degenerative diseases, and the multi-target and multi-gene stable silencing vector is characterized in that multi-gene and multi-target precise gene silencing elements corresponding to genes such as Nogo-A, hBACE1 and PTBP1 are integrated in a second intron of a CCR5 gene of a mesenchymal stem cell in a reverse fixed point manner by using a gene editing technology; therefore, the effect of continuously silencing expression of genes such as Nogo-A, hBACE1 and PTBP1 for a long time is achieved, and a multi-gene multi-target long-time stable silencing vector system is established. The mesenchymal stem cells modified by the multi-gene multi-target stable silencing vector can be used for treating nervous system degenerative diseases including AD (Alzheimer's disease) and PD (Parkinson's disease).
Resumen de: CN120400109A
The invention relates to a polypeptide drug for preventing and treating Alzheimer's disease, which can safely and effectively reduce the protein level of PS1 in AD and inhibit amyloid pathway metabolism of amyloid precursor protein so as to improve pathological deposition of beta amyloid protein in AD. Through an endogenous PS1 protein polypeptide fragment, the effect that PS1 is used for inhibiting PS1 is realized, the specificity is high, the safety is good, the curative effect is exact, the molecular weight is small, and under the help of a cell-penetrating peptide Tat sequence, the PS1 protein polypeptide fragment easily penetrates through a blood brain barrier and smoothly reaches an AD susceptible region to play a role; besides, the compound is easy to synthesize and low in preparation cost, has obvious and unique advantages compared with small molecule chemical inhibitors and monoclonal antibody drugs, can become ideal drugs for preventing and treating AD, and has high clinical conversion value.
Resumen de: CN120392820A
The invention relates to a novel application of small extracellular vesicles with high expression of NAMPT in preparation of drugs for relieving or treating traumatic brain injury. The invention finds that the NAMPT-sEV administration in the nose can obviously increase the expression of Sirtuin 1 of an rmTBI patient, so that tau is deacetylated. Besides, the NAMPT-sEV inhibits neuroinflammation, maintains the polarity of aquapoprotein-4, promotes the repair of a lymphatic system and a meningeal lymphatic system, and is beneficial to the removal of ac-tau protein in brain tissues, and the reduction of the ac-tau protein can prevent the degeneration of an initial axon segment and the wrong positioning of the tau protein. In conclusion, the invention provides that NAMPT-sEV reduces neuron loss of rmTBI and improves cognitive function through various mechanisms, and the small extracellular vesicles highly expressing NAMP can be well used for alleviating or treating traumatic brain injury and dementia including Alzheimer's disease.
Resumen de: CN120398997A
The invention discloses a compound with hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein degradation activity as well as a synthesis method and application thereof. The compound degrades HIF-1alpha protein through a ubiquitin-proteasome pathway, and is suitable for treating diseases such as cancers (such as pancreatic cancer and cervical cancer), encephaledema, atherosclerosis, rheumatoid arthritis, psoriasis, Alzheimer's disease and glaucoma related to overexpression of HIF-1alpha. Experiments show that the compound can significantly degrade HIF-1alpha protein, the synthesis method is simple and convenient, raw materials are easy to obtain, and the compound has wide drug development prospects.
Resumen de: CN120392842A
The invention relates to application of a gaultheria yunnanensis extract in preparation of a medicine for treating cerebral diseases, and particularly relates to application of a gaultheria yunnanensis extract in clinical treatment of Alzheimer's disease, cerebral ischemic disease, Parkinson's disease dementia, traumatic brain injury, chronic traumatic encephalopathy and other diseases. Meanwhile, the clinical disease treatment range of the gaultheria yunnanensis extract is further expanded. Particularly, the traditional Chinese medicine composition has a remarkable curative effect in clinical application of treating the Alzheimer's disease.
Resumen de: WO2025159459A1
The present invention relates to a pharmaceutical composition for preventing or treating degenerative brain diseases, the composition comprising prasugrel as an active ingredient. The composition containing prasugrel or a salt thereof according to the present invention has excellent neuroprotective activity and, in particular, can suppress MPP+-induced neurotoxicity and neuronal cell death, suppress LPS-induced microglial cell activation and cell migration, and has neuroinflammation inhibitory activity, and thus has the effect of preventing, alleviating, and treating various degenerative brain diseases including Parkinson's disease.
Resumen de: US2025241950A1
Provided are chimeric antigen receptor (CAR) that bind to beta amyloid, macrophages (CAR-Ms) that express the CAR, and compositions comprising the same. Also provided are methods for reducing one or more symptoms associated with Alzheimer's disease using the CAR-Ms.
Resumen de: US2025243269A1
The present disclosure provides compositions and methods for treating neurodegenerative diseases, in particular, Alzheimer's Disease, by using anti-FSH antibodies in a subject in need thereof. In some embodiments, the subject has a condition in which FSH levels are elevated. The methods include administering to said subject a therapeutically effective amount of an anti-FSH antibody or an antigen-binding portion thereof.
Resumen de: US2025243172A1
NLRP3 selective inhibitors (NSIs) as anti-inflammatory agents are provided, as are methods of using NSIs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, acute myocardial infarction, heart failure, arthritis, diabetes, gout, COVID-19, and autoinflammatory diseases.
Resumen de: WO2025159427A1
The present invention relates to: an apolipoprotein E (APOE) antisense oligonucleotide; and a pharmaceutical composition for treating Alzheimer's disease comprising same. The antisense oligonucleotide of the present invention can reduce the expression of the APOE4 variant gene that contributes to increased risk and exacerbation of Alzheimer's disease, and can be used as an RNA therapeutic agent for diseases caused by abnormal levels of APOE proteins or APOE variant genome expression.
Nº publicación: WO2025160116A1 31/07/2025
Solicitante:
WOOLSEY PHARMACEUTICALS INC [US]
WOOLSEY PHARMACEUTICALS, INC
Resumen de: WO2025160116A1
A method includes treatment of a sporadic ALS patient with oral fasudil at a dose exceeding 240 mg/day. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
BOPI
Sede Electrónica
